Amgen is rated high risk because it has implemented race- and identity-based policies in philanthropy and employment that prioritize preferential treatment over merit, and it engages heavily in advocacy, funding, and political actions tied to divisive social causes. These practices suggest the company has allowed political activism to shape its governance and business priorities rather than focusing on core business objectives.
